ADVA
20.5.2021 09:02:13 CEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its new compact, low-power edge demarcation solution, giving network operators an easy and cost-efficient route to 10Gbit/s Carrier Ethernet services. The ADVA FSP 150-XG108 Series meets the precise needs of mobile network operators (MNOs) aiming to deliver a faster and more responsive experience by rolling out 5G New Radio equipment at scale. The solution also enables enterprises to affordably extend bandwidth as they push data to the cloud and supports the cost-effective expansion of digitized cable networks. Featuring zero-touch provisioning and 5G timing capabilities, the ADVA FSP 150-XG108 Series is ideal for growing network capacity while reducing footprint, power and cost.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005061/en/
“Today’s MNOs need to be able to seize new revenue opportunities and grow capacity without worrying about increased energy consumption or rack space eating into profitability. That’s where our FSP 150-XG108 Series hits the sweet spot. It provides a quick and seamless way to deploy high-bandwidth Carrier Ethernet services without major cost,” said Christoph Glingener, CTO, ADVA. “Our FSP 150-XG108 Series is engineered for the practical challenges of meeting cloud and 5G demand. It consumes very little power and supports both 1Gbit/s and 10Gbit/s interface speeds in a 1RU footprint. What’s more, with its temperature-hardened design, our FSP 150-XG108 Series removes the need for expensive air-conditioning.”
The ADVA FSP 150-XG108 Series enables network operators to easily and affordably migrate from 1Gbit/s to 10Gbit/s MEF 3.0 services. Using proven and established OAM processes, it offers simple operation and network integration. With zero-touch provisioning, the ADVA FSP 150-XG108 Series removes the need for technically trained onsite staff and makes service activation quick and easy. Its compact design caters for space-restricted applications and its redundant power supply ensures high availability. The ADVA FSP 150-XG108 Series is also well prepared for emerging timing requirements with hardware-assisted BITS, PTP and SyncE synchronization.
“We’re providing the compact, robust and reliable demarcation that mobile, cable and enterprise networks require for massive 10Gbit/s rollout. Our FSP 150-XG108 Series is simple, efficient and highly scalable. With zero-touch provisioning, service activation becomes effortless. The FSP 150-XG108 Series also offers intuitive network control and service monitoring through the automated management of our Ensemble Controller and Ensemble Packet Director,” commented James Buchanan, GM, Edge Cloud, ADVA. “And, despite being optimized for cost-sensitive, high-bandwidth applications, our FSP 150-XG108 Series doesn’t compromise on performance or synchronization. It’s the perfect choice for empowering any network edge with 10Gbit/s demarcation and aggregation.”
Watch this product video for more information: https://youtu.be/pAcqPOtO5eI .
Additional details are also available in this Tech Cam interview: https://youtu.be/bdd-AqvgpBM .
Supporting slides can be viewed here: https://adva.li/fsp-150-xg108-series-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005061/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom